BlackRock’s Impact BioMedical IBO Stock Holding History

BlackRock’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$120K	Hold	259,946	–	–	﹤0.01%	4965
2026 Q1	$156K	Hold	259,946	–	–	﹤0.01%	4854
2025 Q4	$131K	Buy	259,946 +7,216	+3%	+$3.82K	﹤0.01%	4833
2025 Q3	$168K	Hold	252,730	–	–	﹤0.01%	4716
2025 Q2	$164K	Buy	252,730 +222,055	+724%	+$125K	﹤0.01%	4717
2025 Q1	$26.7K	Buy	+30,675	New	+$53.1K	﹤0.01%	5042

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MAC

Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

BlackRock's IBO Position: Q2 2026 in Review

BlackRock held its Impact BioMedical (IBO) position steady in Q2 2026 at 259,946 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #4965.

BlackRock first reported a position in IBO in Q1 2025 and has held it in 6 quarters since. The position peaked at $168K in Q3 2025. 22 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

BlackRock held 259,946 shares of Impact BioMedical worth $120K as of Q2 2026.
BlackRock left its Impact BioMedical share count unchanged in Q2 2026.
Impact BioMedical made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4965 holding.
BlackRock first reported a position in Impact BioMedical in Q1 2025 and has held it in 6 quarters since.
BlackRock's Impact BioMedical position peaked at $168K in Q3 2025.
22 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.